pipeline.

GB001

Phase 2 clinical program*

GB002

Phase 1 clinical program*

GB003

Preclinical program*

GB004

First-in-class, HIF-1α stabilizer, for the treatment of inflammatory bowel diseases – Phase 1 clinical program

*Targets to be disclosed

Now Enrolling: The PROSERA Phase 3 study of seralutinib in adults with Pulmonary Arterial Hypertension (PAH).

Learn more about the study